Qingyu Shen

Seocho, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer.

SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer.

Journal: Oncogene

Published: November 05, 2020

SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.

SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.

Journal: BMB reports

Published: January 17, 2018

MicroRNA-495-3p functions as a tumor suppressor by regulating multiple epigenetic modifiers in gastric carcinogenesis.

MicroRNA-495-3p functions as a tumor suppressor by regulating multiple epigenetic modifiers in gastric carcinogenesis.

Journal: The Journal of pathology

Published: May 24, 2017

Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.

Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: May 22, 2017

T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma.

T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma.

Journal: Experimental & molecular medicine

Published: April 21, 2017

Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.

Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.

Journal: Oncotarget

Published: January 07, 2016

Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer.

Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer.

Journal: Oncotarget

Published: September 14, 2015

Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis.

Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis.

Journal: Journal of Korean medical science

Published: April 14, 2015

MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer.

MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer.

Journal: Oncotarget

Published: October 01, 2014

MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.

MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.

Journal: Journal of hepatology

Published: August 08, 2014

HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.

HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.

Journal: Cancer letters

Published: May 07, 2014

Oncogenic potential of CK2α and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.

Oncogenic potential of CK2α and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.

Journal: The FEBS journal

Published: March 12, 2014

Showing 1-12 of 23

Last Updated: 09/26/2026